Currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off-label use of an investigational drug.
Current Axis I primary psychiatric diagnosis other than major depressive disorder.
Organic mental disease, including mental retardation.
History of clinically significant disease, including any cardiovascular, hepatic, renal, respiratory, hematologic, endocrinologic, or neurologic disease, or clinically significant laboratory abnormality that is not stabilized or is anticipated to require treatment during the study.
Subjects receiving an investigational agent (including different formulation and generic agents of investigational drug) in the previous 3 months prior to screening.
Women in pregnancy or lactation, or female of child bearing potential without appropriate birth control measures.
Use of antipsychotics or mood stabilizers within 5 days prior to screening.
Has received depot antipsychotic medication within one cycle prior to screening.
Known allergy or lack of response to mirtazapine.
Has received ECT or MECT within 3 months prior to screening.
History of anticholinergic drug allergy or complications (allergic reaction, skin rash, urticaria and other allergic reactions which caused by drugs).
Smokers.
Significant risk of suicidal and/or self-harm behaviors

NCT03131050_exc_T2
Condition
psychiatric diagnosis
NCT03131050_exc_T3
Qualifier
primary
NCT03131050_exc_T4
Qualifier
Axis I
NCT03131050_exc_T5
Negation
other than
NCT03131050_exc_T6
Condition
major depressive disorder
NCT03131050_exc_T7
Condition
Organic mental disease
NCT03131050_exc_T8
Condition
mental retardation
NCT03131050_exc_T9
Qualifier
clinically significant
NCT03131050_exc_T10
Condition
disease
NCT03131050_exc_T11
Condition
diovascular, h ease, o
NCT03131050_exc_T12
Condition
ocrinologic, o ease, o
NCT03131050_exc_T13
Condition
atologic, e ease, o
NCT03131050_exc_T14
Condition
piratory, h ease, o
NCT03131050_exc_T15
Condition
al, r ease, o
NCT03131050_exc_T16
Condition
atic, r ease, o
NCT03131050_exc_T17
Condition
neurologic disease
NCT03131050_exc_T18
Qualifier
clinically significant
NCT03131050_exc_T19
Condition
laboratory abnormality
NCT03131050_exc_T20
Negation
not
NCT03131050_exc_T21
Qualifier
stabilized
NCT03131050_exc_T22
Mood
anticipated to require
NCT03131050_exc_T23
Procedure
treatment
NCT03131050_exc_T24
Temporal
during the study
NCT03131050_exc_T25
Scope
not stabilized or is anticipated to require treatment during the study
NCT03131050_exc_T28
Drug
antipsychotics
NCT03131050_exc_T29
Drug
mood stabilizers
NCT03131050_exc_T30
Temporal
within 5 days prior to screening
NCT03131050_exc_T31
Scope
antipsychotics or mood stabilizers
NCT03131050_exc_T32
Drug
depot antipsychotic medication
NCT03131050_exc_T33
Temporal
within one cycle prior to screening
NCT03131050_exc_T34
Condition
allergy
NCT03131050_exc_T35
Condition
lack of response
NCT03131050_exc_T36
Drug
mirtazapine
NCT03131050_exc_T37
Scope
allergy or lack of response
NCT03131050_exc_T38
Temporal
within 3 months prior to screening
NCT03131050_exc_T39
Reference_point
screening
NCT03131050_exc_T40
Reference_point
screening
NCT03131050_exc_T41
Reference_point
screening
NCT03131050_exc_T42
Procedure
ECT
NCT03131050_exc_T43
Procedure
MECT
NCT03131050_exc_T44
Scope
ECT or MECT
NCT03131050_exc_T45
Drug
anticholinergic drug
NCT03131050_exc_T46
Condition
allergy
NCT03131050_exc_T47
Condition
allergic reaction
NCT03131050_exc_T48
Condition
skin rash
NCT03131050_exc_T49
Condition
urticaria
NCT03131050_exc_T50
Condition
allergic reactions
NCT03131050_exc_T51
Drug
drugs
NCT03131050_exc_T52
Qualifier
other
NCT03131050_exc_T53
Scope
allergic reaction, skin rash, urticaria and other allergic reactions
NCT03131050_exc_T54
Scope
allergic reaction, skin rash, urticaria and other allergic reactions which caused by drugs
NCT03131050_exc_T55
Scope
anticholinergic drug allergy
NCT03131050_exc_T56
Observation
Smokers
NCT03131050_exc_T57
Mood
risk of
NCT03131050_exc_T58
Observation
/or self
NCT03131050_exc_T59
Observation
self-harm behaviors
NCT03131050_exc_T60
Scope
suicidal and/or self-harm behaviors